21 results
SC 14D9
NGM
Ngm Biopharmaceuticals Inc
8 Mar 24
Tender offer solicitation
5:21pm
and other commercial counterparties and the risks associated with the foregoing, including as noted below.
Risks Associated with Continued Independence … certain policies and procedures to establish and maintain the independence of its research departments and personnel. As a result, Guggenheim
SC TO-T
EX-99
NGM
Ngm Biopharmaceuticals Inc
8 Mar 24
Third party tender offer statement
4:53pm
the independence of our research departments and personnel. As a result, our research analysts may hold views, make statements or investment recommendations
8-K
EX-99.1
8qnce2jo
6 Jan 21
Results of Operations and Financial Condition
4:24pm
424B5
a55jr8nite4is
6 Jan 21
Prospectus supplement for primary offering
4:23pm
424B5
6yke635s740ge8h
4 Jan 21
Prospectus supplement for primary offering
4:10pm
S-3
EX-1.2
om15fyq31llcsqu5a
5 Jun 20
Shelf registration
5:23pm
DEF 14A
kuo7gs0buc4a
8 Apr 20
Definitive proxy
8:00am
10-K
pr1920si
17 Mar 20
Annual report
4:33pm
424B1
0z29uncevixor29wdbx
4 Apr 19
Prospectus with pricing info
5:21pm
S-1/A
0qd4n nnvz2mudz
25 Mar 19
IPO registration (amended)
12:00am
S-1
EX-3.4
i38ovy8cii6w
28 Sep 18
IPO registration
5:14pm
S-1
y75zq6ll1 efishgs5
28 Sep 18
IPO registration
5:14pm